These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38767914)

  • 1. Federal Trade Commission Oversight of the Pharmaceutical Industry.
    Kapczynski Jd A
    JAMA; 2024 Jun; 331(23):1995-1996. PubMed ID: 38767914
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 4. Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements.
    Sherkow JS
    Nat Biotechnol; 2013 Apr; 31(4):316-7. PubMed ID: 23563426
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 7. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
    Sharkey N
    J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
    [No Abstract]   [Full Text] [Related]  

  • 8. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 9. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 10. RX for nosebleed prices.
    Greenwald J
    Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
    [No Abstract]   [Full Text] [Related]  

  • 11. The Myth of the Free Market for Pharmaceuticals.
    Conti RM; Frank RG; Cutler DM
    N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106
    [No Abstract]   [Full Text] [Related]  

  • 12. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 13. REMS violations fines.
    Shaffer C
    Nat Biotechnol; 2009 Dec; 27(12):1068. PubMed ID: 20010568
    [No Abstract]   [Full Text] [Related]  

  • 14. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 17. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 18. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 19. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 20. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.